Tavapadon Parkinson Decision Nears: TEMPO Data and Where It Could Fit

Tavapadon Parkinson disease development is under active FDA review after AbbVie’s September 2025 NDA. With four TEMPO trials reported, the question for clinicians is where a D1/D5-selective dopamine partial agonist would sit alongside levodopa.

April 26, 2026 · 4 min read

Why Tavapadon Parkinson Is in the News

Tavapadon Parkinson disease development reached the FDA in September 2025, when AbbVie submitted a new drug application (NDA) covering both early-stage monotherapy and adjunctive use with levodopa. The agency has accepted the filing, and a regulatory decision is anticipated during 2026.

The new drug application is supported by three randomized, placebo-controlled Phase 3 trials — TEMPO-1, TEMPO-2, and TEMPO-3 — plus an interim analysis of the open-label extension TEMPO-4 presented at the 2025 International Congress of Parkinson’s Disease and Movement Disorders.

The Background

Levodopa remains the gold standard for Parkinson disease (PD) motor symptoms. Existing oral and transdermal dopamine agonists (pramipexole, ropinirole, rotigotine) primarily activate D2-like receptors and carry well-recognized side effects: somnolence, peripheral edema, hallucinations, and impulse control disorders (ICDs).

Tavapadon is structurally and pharmacologically distinct — a once-daily oral D1/D5 partial agonist. By engaging the direct basal ganglia pathway, it aims to deliver motor benefit while sidestepping the D2/D3-mediated side-effect burden. AbbVie acquired the program through its Cerevel Therapeutics acquisition.

The Tavapadon Parkinson Evidence So Far

The TEMPO Phase 3 program produced three controlled trials and one open-label extension across early and advanced disease.

TEMPO-1 (n = 529, fixed-dose monotherapy): MDS-UPDRS Parts II and III combined score at week 26 — placebo +1.8; tavapadon 5 mg −9.7; 15 mg −10.2 (p < 0.0001 versus placebo)
TEMPO-2 (n = 304, flexible-dose 5–15 mg monotherapy): MDS-UPDRS Parts II and III combined score at week 26 — placebo −1.2; tavapadon −10.3 (p < 0.0001); MDS-UPDRS Part II key secondary also met
TEMPO-3 (n = 507, flexible-dose adjunctive to levodopa in motor fluctuators): change in good “ON” time without troublesome dyskinesia at week 27 — tavapadon +1.7 hours versus placebo +0.6 hours (1.1-hour difference; p < 0.0001), with significant reduction in OFF time
TEMPO-4 (open-label extension, interim n = 991 pooled): safety profile sustained over 58 weeks; most common treatment-emergent adverse events were nausea (11.0%), dizziness (10.6%), headache (9.6%), and falls (9.2%), with no new safety signals identified

Where Experts Disagree

The headline efficacy is consistent across trials, but informed observers diverge on positioning and tolerability.

“Tavapadon has the potential to offer an important new option for Parkinson’s.” — Hubert Fernandez, MD, Director, Center for Neurological Restoration, Cleveland Clinic (TEMPO-2 global principal investigator; AbbVie relationship disclosed)

Market analysts and key opinion leaders surveyed by GlobalData have offered a more cautious read. They note that dopamine agonists are no longer preferred adjunctive therapies for many movement-disorder specialists because of ICD, somnolence, and hallucination risk, putting the burden on tavapadon’s selectivity story to differentiate it from already-generic competitors.

The discontinuation pattern is also worth weighing: in TEMPO-1, 18.1% of tavapadon-treated patients stopped because of adverse events versus 4.0% on placebo, mostly during titration. That signal will shape real-world adherence even if the mechanism delivers on its promise.

The Practical Question for Clinicians

The practical question for movement-disorder neurologists is whether tavapadon Parkinson treatment will earn the early-PD monotherapy slot, the adjunctive role in fluctuators, or both — and which patient profile benefits most.

In early disease, the roughly 10-point MDS-UPDRS improvement versus placebo would compete with starting low-dose levodopa or an existing D2-agonist; the D1/D5-selective profile may appeal to patients at higher baseline risk for ICDs or somnolence. In motor-fluctuation patients, the 1.1 additional good-ON-hours from TEMPO-3 are clinically meaningful but in line with what other adjunctive agents can deliver.

What to Watch For

The FDA’s tavapadon Parkinson decision in 2026 — and how the labeling handles early monotherapy versus adjunctive use
Full peer-reviewed publication of TEMPO-1, TEMPO-2, and TEMPO-3 with effect sizes, confidence intervals, and complete safety data
Whether post-marketing experience confirms the lower D2/D3-mediated AE profile (ICDs, somnolence, hallucinations)
The TEMPO-4 final readout (estimated completion January 2026) for longer-term tolerability and durability
Real-world titration tolerance, given the higher early-discontinuation signal in TEMPO-1

Sources

NeurologyLive. NDA Filed for Tavapadon as Once-Daily Oral Therapy for Parkinson Disease. September 2025. NeurologyLive — AbbVie’s NDA Submission for Tavapadon
NeurologyLive. Parkinson Agent Tavapadon Meets Primary and Secondary End Points as Monotherapy in Phase 3 TEMPO-1 Trial. 2024. NeurologyLive — TEMPO-1 Topline Results
AbbVie / PR Newswire. AbbVie Announces Positive Topline Results for the Phase 3 TEMPO-2 Trial Evaluating Tavapadon as a Monotherapy for Parkinson’s Disease. December 9, 2024. AbbVie Press Release — TEMPO-2 Topline Results
Practical Neurology. For People with Parkinson Disease, Tavapadon Adjunctive Therapy to Levodopa Increased Good ON Time. 2025. Practical Neurology — TEMPO-3 Adjunctive Therapy Results
NeurologyLive. Parkinson Agent Tavapadon Shows Continued Efficacy, Safety in Phase 3 TEMPO-4 Trial. 2026. NeurologyLive — TEMPO-4 Interim Long-Term Safety Data
Medscape. Novel Medication Improves Motor Symptoms in Early and Advanced Parkinson’s Disease. 2026. Medscape — Detailed TEMPO-1 and TEMPO-3 Safety Profile
NeurologyLive. Previewing Expected FDA Decisions in Neurology for 2026. 2026. NeurologyLive — 2026 Neurology FDA Decision Preview
U.S. National Library of Medicine. Trial of Tavapadon as Monotherapy in Adults With Early Parkinson’s Disease (TEMPO-1). ClinicalTrials.gov. ClinicalTrials.gov — TEMPO-1 Study Record (NCT04201093)